NeuroOne Medical Technologies Gets FDA Clearance for OneRF Trigeminal Nerve Ablation System
MT Newswires Live
Aug 18
NeuroOne Medical Technologies (NMTC) said Monday that the US Food and Drug Administration has cleared its OneRF Trigeminal Nerve Ablation System for procedures treating chronic pain and for functional neurosurgery.
The device targets trigeminal neuralgia, a severe facial pain condition affecting about 150,000 people annually in the US.
NeuroOne said the clearance builds on its proprietary RF generator platform and allows the company to move forward with a limited commercial launch in Q4, ahead of earlier expectations.
Shares of NeuroOne were up more than 18% in Monday's premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.